X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1315) 1315
Book Review (113) 113
Conference Proceeding (63) 63
Publication (40) 40
Patent (32) 32
Book Chapter (3) 3
Book / eBook (1) 1
Data Set (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (473) 473
humans (455) 455
gastroenterology & hepatology (443) 443
gastroenterology and hepatology (315) 315
male (268) 268
female (261) 261
adult (247) 247
crohn's disease (191) 191
inflammatory-bowel-disease (182) 182
middle aged (173) 173
inflammatory bowel disease (149) 149
abridged index medicus (146) 146
ulcerative colitis (146) 146
crohns-disease (142) 142
infliximab (126) 126
ulcerative-colitis (113) 113
crohn disease - drug therapy (108) 108
treatment outcome (96) 96
adolescent (91) 91
aged (86) 86
risk factors (84) 84
care and treatment (78) 78
inflammatory bowel diseases (78) 78
young adult (72) 72
therapy (69) 69
organic chemistry (58) 58
severity of illness index (57) 57
analysis (54) 54
antibodies, monoclonal - therapeutic use (54) 54
gastrointestinal diseases (53) 53
crohn disease - diagnosis (52) 52
immunosuppressive agents - therapeutic use (51) 51
adalimumab (50) 50
clinical trials (50) 50
remission induction (49) 49
life sciences (46) 46
double-blind method (45) 45
ibd (45) 45
tumor necrosis factor-alpha - antagonists & inhibitors (45) 45
follow-up studies (44) 44
remission (44) 44
azathioprine (43) 43
colitis, ulcerative - drug therapy (43) 43
crohns disease (43) 43
colitis (41) 41
crohn disease - pathology (41) 41
maintenance therapy (41) 41
retrospective studies (41) 41
gastrointestinal agents - therapeutic use (40) 40
c-reactive protein (39) 39
child (39) 39
crohn disease - genetics (38) 38
time factors (38) 38
animals (37) 37
gastroenterology (37) 37
inflammation (37) 37
medical colleges (37) 37
medical research (37) 37
risk (37) 37
incidence (35) 35
inflammatory bowel diseases - drug therapy (35) 35
quality of life (35) 35
efficacy (34) 34
prospective studies (34) 34
rheumatoid-arthritis (34) 34
surgery (34) 34
anti-inflammatory agents - therapeutic use (33) 33
chemistry (33) 33
crohn disease - complications (33) 33
crohn disease - immunology (33) 33
management (33) 33
endoscopy (32) 32
metallurgy (32) 32
patients (32) 32
research (32) 32
chemical sciences (31) 31
health aspects (31) 31
intestinal mucosa - pathology (31) 31
prognosis (31) 31
diagnosis (30) 30
intestine (30) 30
medicine, experimental (30) 30
mice (30) 30
pharmacology & pharmacy (30) 30
crohn disease - surgery (29) 29
recurrence (29) 29
aged, 80 and over (28) 28
case-control studies (28) 28
drug therapy, combination (28) 28
epidemiology (28) 28
immunosuppressive agents - adverse effects (28) 28
microbiology (28) 28
peptides (28) 28
antibodies, monoclonal - adverse effects (27) 27
colitis, ulcerative - diagnosis (27) 27
crohn disease - epidemiology (27) 27
crohn disease - therapy (27) 27
human necessities (27) 27
hygiene (27) 27
medical or veterinary science (27) 27
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gut, ISSN 0017-5749, 05/2017, Volume 66, Issue 5, pp. 839 - 851
ObjectiveVedolizumab is a gut-selective antibody to α4β7 integrin for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). We report an... 
INFLAMMATORY-BOWEL-DISEASE | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | OPPORTUNISTIC INFECTIONS | FOLLOW-UP | RISK | EXPERIENCE | COHORT | INDUCTION | GASTROENTEROLOGY & HEPATOLOGY | ADVERSE EVENTS | MAINTENANCE THERAPY | Tuberculosis - epidemiology | Age Factors | Humans | Middle Aged | Male | Narcotics - therapeutic use | Clostridium Infections - epidemiology | Adrenal Cortex Hormones - therapeutic use | Incidence | Young Adult | Treatment Failure | Infusions, Intravenous - adverse effects | Gastrointestinal Agents - immunology | Adult | Female | Colitis, Ulcerative - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Risk Factors | Sepsis - epidemiology | Chemical and Drug Induced Liver Injury - epidemiology | Randomized Controlled Trials as Topic | Crohn Disease - drug therapy | Gastrointestinal Agents - therapeutic use | Gastrointestinal Agents - adverse effects | Antibodies, Monoclonal, Humanized - immunology | Antibodies, Neutralizing - blood | Leukoencephalopathy, Progressive Multifocal - epidemiology | Neoplasms - epidemiology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Drug therapy | Crohn's disease | Ulcerative colitis | Clinical trials | Infections | Malignancy | Patients | Risk factors | Crohns disease | Inflammatory bowel disease | Studies | Tuberculosis | Tumor necrosis factor | Population | Tumor necrosis factor-TNF | TNF inhibitors | Sepsis | Safety | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus | 1506 | Inflammatory Bowel Disease
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 8, pp. 699 - 710
Journal Article
Gastroenterology, ISSN 0016-5085, 07/2016, Volume 151, Issue 1, pp. 212 - 213
Journal Article
Gastroenterology, ISSN 0016-5085, 07/2016, Volume 151, Issue 1, pp. 212 - 213
Journal Article
Gastroenterology, ISSN 0016-5085, 07/2016, Volume 151, Issue 1, pp. 212 - 213
Journal Article
Journal Article
Gastroenterology, ISSN 0016-5085, 2016, Volume 151, Issue 1, pp. 212 - 213
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 147, Issue 3, pp. 618 - 627.e3
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2010, Volume 362, Issue 15, pp. 1383 - 1395
Journal Article
Journal Article
Gastroenterology, ISSN 0016-5085, 2012, Volume 142, Issue 1, pp. 63 - 70.e5